Supply Chain Intelligence

Rani Therapeutics Holdings, Inc. Supply Chain

RANI supply chain intelligence for Rani Therapeutics Holdings, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

RANI ·Last updated 2026-09-14 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

10Suppliers
20Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Rani Therapeutics Holdings, Inc. (RANI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

34Total relationships
2Distinct source URLs
6High confidence
0.727Average confidence
2026-09-14Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Rani Therapeutics Holdings, Inc. Suppliers

TickerNameConfidenceEvidence
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreemen…
JNJ Johnson & Johnson 72% entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter…
LLY Eli Lilly and Company 72% entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter…
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreemen…
NVO Novo Nordisk A/S 72% Reciprocal relationship from NVO graph: Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreemen…
NVO Novo Nordisk A/S 72% entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from RANI graph: uct. The FDA regulations require that products be manufactured in specific approved facilities and in accordance wit…
ORANY ORANY 72% uct. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP. Biologics manufacturers and their subcontractors are required to register t…
PTGX Protagonist Therapeutics, Inc. 72% Reciprocal relationship from PTGX graph: Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreeme…
PTGX Protagonist Therapeutics, Inc. 72% entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter…

Rani Therapeutics Holdings, Inc. Customers

TickerNameConfidenceEvidence
CHUGAI CHUGAI 92% the exclusive license granted to Chugai, technology transfer of a sterile manufacturing process, sales-based milestones, and royalties are accounted for under ASC 606
CHUGAI-PHARMACEUTICAL-CO-LTD CHUGAI-PHARMACEUTICAL-CO-LTD 85% rued professional fees 851 718 Accrued rent 328 335 Accrued preclinical and clinical trial costs — 198 Other 97 46 Total accrued expenses and other current liabilities $ 4,706 $ 3,943 6. Evaluation, …
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from RANI graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from RANI graph: Reciprocal relationship from JNJ grap…
JNJ Johnson & Johnson 72% entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter…
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from RANI graph: Reciprocal relationship from LLY graph: Reciprocal relationship from RANI graph: Reciprocal relationship from LLY grap…
LLY Eli Lilly and Company 72% entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter…
NVO Novo Nordisk A/S 72% Reciprocal relationship from NVO graph: Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreemen…
NVO Novo Nordisk A/S 72% entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter…
ORANY ORANY 72% uct. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP. Biologics manufacturers and their subcontractors are required to register t…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from RANI graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from RANI graph: uct. The FDA regulations require …
PTGX Protagonist Therapeutics, Inc. 72% Reciprocal relationship from PTGX graph: Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreeme…
PTGX Protagonist Therapeutics, Inc. 72% entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter…
AMENDED-RANI-LLC AMENDED-RANI-LLC 62% ted States, Canada, Europe (including the United Kingdom) and Australia, and ProGen will lead development and commercialization in all other countries. Each party has the right to opt-out of the Coll…
AMENDED-RANI-LLC-AGREEMENT-AS-CONTINUING-LLC AMENDED-RANI-LLC-AGREEMENT-AS-CONTINUING-LLC 62% ted States, Canada, Europe (including the United Kingdom) and Australia, and ProGen will lead development and commercialization in all other countries. Each party has the right to opt-out of the Coll…
AMENDED-RANI-LLC-AGREEMENT-RANI-LLC AMENDED-RANI-LLC-AGREEMENT-RANI-LLC 62% sion of $ 6.0 million of the previously outstanding loan's principal balance), before deducting placement agent fees and other expenses payable by the Company of approximately $ 4.5 million, and excl…
CHIEF-EXECUTIVE-OFFICER-INCUBE-LABS-LLC CHIEF-EXECUTIVE-OFFICER-INCUBE-LABS-LLC 62% ted States, Canada, Europe (including the United Kingdom) and Australia, and ProGen will lead development and commercialization in all other countries. Each party has the right to opt-out of the Coll…
INCUBE-LABS-LLC INCUBE-LABS-LLC 62% ently on the market with convenient, oral dosing. We do not have any products approved for sale, and we have not yet generated any revenue from sales of a commercial product. Our ability to generate …
LEASE-RANI-LLC LEASE-RANI-LLC 62% ted States, Canada, Europe (including the United Kingdom) and Australia, and ProGen will lead development and commercialization in all other countries. Each party has the right to opt-out of the Coll…
PROGEN-CO-LTD PROGEN-CO-LTD 62% llaboration and License Agreement at will, without cause, by providing the Company with 60 days’ prior written notice. Upon termination, Chugai must wind down development, regulatory, and commercial …
RANI-HOLDINGS RANI-HOLDINGS 62% icted Stock Units Weighted Average Grant-Date Fair Value per Share Balance at December 31, 2025 348,702 $ 6.94 Vested ( 123,389 ) $ 9.69 Forfeited — $ — Balance at March 31, 2026 225,313 $ 5.44 As of…

Rani Therapeutics Holdings, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
RANI-DEBT-12048 Xbrl Convertible 90% xbrl convertible detail from xbrl 2020-12-31.
RANI-DEBT Debt stack $3.9M 90% Market cache reports total debt of $3.9M.
RANI-DEBT-12047 Warrants outstanding: 3 90% xbrl warrant detail from xbrl 2025-12-31.

Rani Therapeutics Holdings, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Rani Therapeutics Holdings, Inc..

Rani Therapeutics Holdings, Inc. Ownership

HolderNameConfidenceEvidence
RANI-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC VANGUARD CAPITAL MANAGEMENT LLC 90% 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 75 tracked holders.

Rani Therapeutics Holdings, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
LLY Eli Lilly and Company 100.00 1 ['customer', 'supplier']
PTGX Protagonist Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
NVO Novo Nordisk A/S 100.00 1 ['customer', 'supplier']
ORANY ORANGE 100.00 1 ['customer', 'supplier']
JNJ Johnson & Johnson 100.00 1 ['customer', 'supplier']
CHUGAI CHUGAI 63.48 1 ['receiving']
CPRX Catalyst Pharmaceuticals, Inc. 50.00 2
CTNM Contineum Therapeutics, Inc. 50.00 2
BLTE Belite Bio, Inc 50.00 2
CYCN Cyclerion Therapeutics, Inc. 50.00 2
D Dominion Energy, Inc. 50.00 2
DAWN Day One Biopharmaceuticals Inc 50.00 2
AXSM Axsome Therapeutics, Inc. 50.00 2
DARE Daré Bioscience, Inc. 50.00 2
ANIK Anika Therapeutics, Inc. 50.00 2
AMZE Amaze Holdings, Inc. 50.00 2
CYTOF Altamira Therapeutics Ltd. 50.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 50.00 2
CANF Can-Fite BioPharma Ltd. 50.00 2
AYTU Aytu BioPharma, Inc. 50.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Rani Therapeutics Holdings, Inc..

Unlock full RANI data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
RANI
Unlock RANI Supply Chain Data
Verified relationships include:
JNJJohnson & JohnsonSupplier72%
JNJJohnson & JohnsonSupplier72%
CHUGAICHUGAICustomer92%
CHUGAI-PHARMACEUTICAL-CO-LTDCHUGAI-PHARMACEUTICAL-CO-LTDCustomer85%
+30 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →